Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) has shared an announcement.
ImpediMed Limited has called an Extraordinary General Meeting to be held on 11 June 2026 in Sydney, providing shareholders with formal notice and a voting form to consider resolutions put forward by the board. The meeting underscores the company’s ongoing governance and shareholder engagement processes, signalling forthcoming decisions that may influence its strategic direction and corporate structure.
The convening of an EGM indicates that ImpediMed may be seeking shareholder approval for matters beyond routine business, which could have implications for management priorities or capital planning. Stakeholders will closely watch the meeting outcomes for any changes that might affect the company’s operations, funding approach, or positioning within the medical technology sector.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company listed on the ASX, focused on developing and commercialising bioimpedance-based devices and related solutions for clinical and healthcare applications. The company targets hospitals and clinicians, aiming to improve patient diagnosis and management through non-invasive measurement technologies in specialist care settings.
Average Trading Volume: 3,581,459
Technical Sentiment Signal: Sell
Current Market Cap: A$17.54M
For an in-depth examination of IPD stock, go to TipRanks’ Overview page.